Allarity Therapeutics (ALLR) expects late Q2 10-Q after audit review

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. filed a notice that its Quarterly Report on Form 10-Q for the period ended June 30, 2025 will be filed late. The company says its financial statements for the quarter are still being reviewed by its certifying auditors and that this review must be completed before the report can be finalized.

Management states that filing the Form 10-Q and related XBRL exhibit by the original deadline would require unreasonable effort or expense, but it reasonably believes the report will be completed and filed within the allowed five-day extension period.

Insights

SEC reporting and disclosure analyst

Allarity seeks a brief extension to file its Q2 2025 10-Q due to ongoing auditor review.

Allarity Therapeutics, Inc. has notified regulators that its Form 10-Q for the quarter ended June 30, 2025 will not be filed by the standard deadline. The company explains that its quarterly financial statements are still under review by its certifying auditors and that this work must be finished before the report can be finalized.

By using a Form 12b-25, the company relies on a rule that allows extra time when a filing cannot be completed without unreasonable effort or expense. It indicates that it expects to file the Form 10-Q, including the XBRL exhibit, within the five-calendar-day extension period permitted for quarterly reports, framing this as a timing and process issue rather than providing any detail about results.

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
		FORM 12b-25	SEC FILE NUMBER 001-41160
		NOTIFICATION OF LATE FILING	CUSIP NUMBER

(Check one):	o Form 10-K	o Form 20-F	o Form 11-K
	x Form 10-Q	o Form 10-D	o Form N-CEN	o Form N-CSR

For Period Ended: June 30, 2025

 o Transition Report on Form 10-K

 o Transition Report on Form 20-F

 o Transition Report on Form 11-K

 o Transition Report on Form 10-Q

 o For the Transition Period Ended:

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Allarity Therapeutics, Inc.

Full Name of Registrant

Former Name if Applicable

123 E Tarpon Ave

Address of Principal Executive Office (Street and Number)

Tarpon Springs, FL 34689

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The registrant’s financial statements for the quarter ended June 30, 2025 are currently being reviewed by its certifying auditors, which review has not been completed as of this date. This review must be completed in order to finalize the registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Management has determined that the registrant will be unable to finalize the Form 10-Q and XBRL exhibit to the report prior to the filing deadline without unreasonable effort or expense. Management reasonably believes that it will be able to complete and file the Form 10-Q within the prescribed extension period.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Jeff Ervin		401		426-4664
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

	Allarity Therapeutics, Inc.
	(Name of Registrant as Specified in Charter)
	has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:		August 14, 2025			By:	/s/ Jeff Ervin
						Jeff Ervin, Chief Financial Officer

3

FAQ

Why is Allarity Therapeutics (ALLR) filing its Q2 2025 Form 10-Q late?

Allarity Therapeutics states that its financial statements for the quarter ended June 30, 2025 are still being reviewed by its certifying auditors, and this review must be completed before the Form 10-Q can be finalized.

When does Allarity Therapeutics expect to file the delayed Q2 2025 Form 10-Q?

The company indicates it reasonably believes it will be able to complete and file the Form 10-Q, along with the XBRL exhibit, within the five-calendar-day extension period allowed for quarterly reports.

What rule is Allarity Therapeutics relying on for the late Q2 2025 10-Q filing?

Allarity is using Rule 12b-25, which allows an extension when a report cannot be filed on time without unreasonable effort or expense, provided the company files the report within the specified extension period.

Does the Allarity Therapeutics NT 10-Q mention significant changes in results of operations?

The document includes the required question about whether significant changes in results of operations are anticipated, but the excerpt does not show any narrative or quantitative explanation regarding such changes.

Who signed Allarity Therapeutics’ notification of late filing for the Q2 2025 Form 10-Q?

The notification was signed on behalf of Allarity Therapeutics, Inc. by Jeff Ervin, who is identified as the Chief Financial Officer.

What period does Allarity Therapeutics’ delayed Form 10-Q cover?

The delayed Form 10-Q relates to the quarterly period ended June 30, 2025.